All In Biotech

Drug Trial Radar · NCT05172245

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase 1/1b Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Sep 19, 2022

Primary completion

Jul 1, 2027

Study completion Jul 1, 2027

Sponsor

Sponsor type
NIH
First posted
Dec 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin, which is a chemotherapy used in this trial, is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib in combination with chemo-radiation may be better than chemo-radiation alone in treating patients with advanced head and neck cancer.

Conditions

  • Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Head and Neck Carcinoma of Unknown Primary
  • Locally Advanced Head and Neck Squamous Cell Carcinoma
  • Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
  • Locally Advanced Laryngeal Squamous Cell Carcinoma
  • Locally Advanced Nasal Cavity Squamous Cell Carcinoma
  • Locally Advanced Oral Cavity Squamous Cell Carcinoma
  • Locally Advanced Oropharyngeal Squamous Cell Carcinoma
  • Locally Advanced Paranasal Sinus Squamous Cell Carcinoma
  • Locally Advanced Sinonasal Squamous Cell Carcinoma
  • Maxillary Sinus Squamous Cell Carcinoma
  • Stage III Hypopharyngeal Carcinoma AJCC v8
  • Stage III Laryngeal Cancer AJCC v8
  • Stage III Lip and Oral Cavity Cancer AJCC v8
  • Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage III Sinonasal Cancer AJCC v8
  • Stage IVA Hypopharyngeal Carcinoma AJCC v8
  • Stage IVA Laryngeal Cancer AJCC v8
  • Stage IVA Lip and Oral Cavity Cancer AJCC v8
  • Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IVA Sinonasal Cancer AJCC v8
  • Stage IVB Hypopharyngeal Carcinoma AJCC v8
  • Stage IVB Laryngeal Cancer AJCC v8
  • Stage IVB Lip and Oral Cavity Cancer AJCC v8
  • Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IVB Sinonasal Cancer AJCC v8

Interventions

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • CisplatinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • IpatasertibDrug

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Radiation TherapyRadiation

    Undergo radiation therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) and recommended phase 2 dose of ipatasertib in combination with definitive chemo-radiationTime frame: At the completion of dose escalation phase, up to 56 days from treatment start date

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Kansas Clinical Research Center

    Fairway, Kansas · Recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas · Recruiting

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky · Active not recruiting

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Rutgers New Jersey Medical School

    Newark, New Jersey · Recruiting

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York · Recruiting

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York · Recruiting

  • Carolinas Medical Center/Levine Cancer Institute

    Charlotte, North Carolina · Active not recruiting

  • Atrium Health Cabarrus/LCI-Concord

    Concord, North Carolina · Active not recruiting

  • University of Cincinnati Cancer Center-UC Medical Center

    Cincinnati, Ohio · Recruiting

  • University of Cincinnati Cancer Center-West Chester

    West Chester, Ohio · Recruiting

  • University of Virginia Cancer Center

    Charlottesville, Virginia · Suspended

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia · Recruiting

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, Canada · Suspended

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.